AlgiPharma AS   Report issue

For profit Phase 2 Phase 3
Founded: Sandvika Norway (2006)

Organization Overview

First Clinical Trial
2009
NCT00970346
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

AlgiPharma AS | AlgiPharma Pty Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

oligog cf-5/20 (4 trials)

Drugs in Phase 2 Trials (2)

sodium alginate (2 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burkholderia Infections (Phase 2)

Cystic Fibrosis (Phase 3)

Fibrosis (Phase 3)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3